Fulcrum repurpose drug for FSHD

Published Date
24/04/2019
Author
Beatriz Bustillo Ramirez
Category
Research
Orange box stating: Breaking news research

Update August 2019: Fulcrum has announced in a press release that the ReDUX4 trial testing losmapimod has been initiated. The trial has sites in the US, Canada, Germany, Spain and France. More information can be found at clinicaltrials.gov. Fulcrum will also initiate a longer open-label study in parallel to the ReDUX4 trial. More information can be found on clinicaltrials.gov

Update July 2019: Fulcrum Therapeutics has launched two Phase 2 clinical trials testing losmapimod in adults with FSHD. The studies will take place in the Netherlands, US and Canada. More information is available on clinicaltrials.gov.

April 2019: Fulcrum Therapeutics has obtained rights to losmapimod from GlaxoSmithKline (GSK). This drug has been tested in 24 clinical trials for multiple indications, including heart and lung disease, so it is known to be generally safe. Fulcrum is interested in losmapimod because it has found that the drug can switch off DUX4 in cells originating from people with facioscapulohumeral muscular dystrophy (FSHD). The company plans to initiate phase 2 trials testing losmapimod in people with FSHD in mid 2019. For more information, read Fulcrum’s press release.

 

If you have any questions about losmapimod or any other FSHD research, please contact the MDUK Research Line on 020 7803 4813 or email research@musculardystrophyuk.org.

Keep in touch